Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Pathologic complete response among patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A meta-analysis.
Authors
Charles Gaber
University of Illinois-Chicago, Chicago, IL
Charles Gaber , Jyotirmoy Sarker , Abdullah Abdelaziz , Ebere Okpara , Todd Lee , Samuel J. Klempner , Ryan David Nipp
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 305)
DOI
10.1200/JCO.2024.42.3_suppl.305
Abstract #
305
Poster Bd #
E5
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Neoadjuvant chemoradiotherapy (NCRT) compared with chemotherapy (NCT) in locally advanced squamous-cell cancer of the esophagus.
First Author: Xue Li
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Locally advanced esophageal cancer: Evaluation of prognosis by assessment of the “yp” stage based on the neoadjuvant regimen received.
First Author: Indika Gunadasa
Poster
2020 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy (TPF regimen) followed with robotic surgery and its impact on outcome in management of esophageal cancers: Indian experience.
First Author: S.P. Somashekhar
Poster
2018 ASCO Annual Meeting
Induction chemoradiotherapy for esophageal cancer: Comparing CROSS regimen with cisplatin/5-FU.
First Author: Abraham Geller